ストックスクリーナーアプリを入手
44.63
1.11%
-0.5291
Novo Nordisk Adr (NVO) 最新ニュース
Novo Nordisk stock extends buyback as trial updates and obesity growth shape outlook - AD HOC NEWS
Novo Nordisk (NYSE: NVO) has bought back 32M shares, with its 12‑month repurchase plan still running - Stock Titan
Novo Nordisk stock heads into the open after a 2.3% slide - AD HOC NEWS
Is Novo Nordisk Stock Still Too Cheap for Investors to Ignore? - The Motley Fool
Novo Nordisk stock falls as heart drug trials are halted despite pediatric obesity win - AD HOC NEWS
NVO Stock Quote Price and Forecast - CNN
Eli Lilly vs. Novo Nordisk: One Has 39% Upside. I'm Picking the Other. - Barchart.com
Novo Nordisk A/Sshare repurchase programme - Finansavisen
Novo Nordisk trial shows semaglutide helped 40% of children - Investing.com
Weekly Recap: Oral Wegovy launch in Germany and DKK8.7077bn buyback - TradingView
Novo Nordisk stock dips as Wegovy pill launch in Germany reshapes obesity market - AD HOC NEWS
European ADRs Push Higher In Wednesday Session Led By ING, IHG, And Novo Nordisk - foreignpolicyjournal.com
From hunger to obesity: Developing world faces growing threat to child health By Reuters - Investing.com
European ADRs Inched Higher As Healthcare Led Gains - Finimize
Novo Nordisk stock reacts to downgrade as oral obesity push advances in Asia - AD HOC NEWS
European ADRs Slipped In US Trading Late Thursday Morning - Finimize
Novo Nordisk stock softens after Q2 upgrade and dividend payout - AD HOC NEWS
Weekly Recap: DKK11.2bn B-share buyback and Wegovy UK/UAE uptake - TradingView
Novo Nordisk stock firms as new Wegovy pill study follows raised 2026 outlook - AD HOC NEWS
Novo Nordisk Shares (NYSE:NVO) Gain 1.9% as $50 Medicare Wegovy Access Trial Challenges Pricing - ts2.tech
Novo Nordisk stock steadies after Q2 growth as buyback milestone is reached - Ad-hoc-news.de
Novo Nordisk stock benefits as France moves to reimburse Wegovy and new obesity trial begins - Ad-hoc-news.de
Novo Nordisk stock holds gains as obesity drug coverage in France supports long-term demand - Ad-hoc-news.de
Novo Nordisk stock steadies after Q2 2026 guidance raise and obesity pill volatility - Ad-hoc-news.de
Weekly Recap: Berenberg cuts NOVO_B and court orders Sun Pharma approval - TradingView
Novo Nordisk (NVO) Sues A Rival Over Obesity Drug Advertising Claims - Sahm
Novo Nordisk stock slips as obesity battle with Lilly and broker downgrade weigh on valuation - Ad-hoc-news.de
Novo Nordisk stock slips after Berenberg downgrade as guidance and competition reshape the outlook - Ad-hoc-news.de
ETFs Investing in Novo Nordisk A/S Sponsored ADR Class B Stocks - TradingView
Why Does Novo Nordisk (NYSE:NVO) Matter to S&P 500 Healthcare? - Kalkine Media
Scholar Rock Overcomes Manufacturing Hurdle to Keep Lead Drug FDA Review on Schedule - Sahm
EBITDA per share of Novo Nordisk A/S ADR Cert Deposito Arg Repr 0.142857 ADR-B – BCBA:NVO.CI - TradingView
Novo Nordisk A/S ADR Cert Deposito Arg Repr 0.142857 ADR-B Revenue Breakdown – BCBA:NVO.CI - TradingView
Preferred dividends of Novo Nordisk A/S ADR Cert Deposito Arg Repr 0.142857 ADR-B – BCBA:NVO.CI - TradingView
Novo Nordisk A/S ADR Cert Deposito Arg Repr 0.142857 ADR-B - TradingView
Novo Nordisk NVO: $47.26 After Guidance Raise, Bull $64 - FinanceFeeds
Novo Nordisk Share Price Forecast | Q2 Earnings, Raised Guidance - Capital.com
Novo Nordisk's Track Record of Internal Innovation Supports a Wide Moat, but Diversification Needed - Morningstar
Novo Nordisk (CPH:NOVO-B; NYSE:NVO) ADR drops after Q2 results outpace forecasts, paving way for possible rebound in Copenhagen - TechStock²
Novo Nordisk reports adjusted operating profit of DKK 33,389 million for Q2 2026 and raises full-year outlook - Finansavisen
Novo Nordisk raises adjusted sales and adjusted operating profit outlook for 2026 - Finansavisen
Novo Nordisk (NYSE: NVO) updates DKK 7,533,256,457 share repurchases - Stock Titan
Weight loss stock wars: Key metrics to watch in Eli Lilly and Novo Nordisk results - Investing.com
Novo Nordisk (NYSE:NVO) Ziltivekimab Trial Fails In Late Stage Cardiovascular Study - Sahm
European ADRs Slipped In US Trading Friday Morning - Finimize
Novo Nordisk provides update on the ZEUS phase 3 trial in people with ASCVD, CKD and inflammation - Finansavisen
Novo Nordisk shares fall after ZEUS trial disappointment highlights 94% sales reliance - TechStock²
Novo Nordisk must face fraud lawsuit over CagriSema trial, judge rules - Investing.com Nigeria
0.37%
0.43%
大文字化:
|
ボリューム (24 時間):